English
Choose your country/region and language
Your experience may change as only information for the country or region you select will be presented.
Disclaimer: Articles are presented for educational purposes only and are not intended to promote any Beckman Coulter product or service. Unless otherwise indicated, Beckman Coulter did not provide funding for these studies.
Featured Scientific & Clinical Studies
- DxC 500i Clinical Analyzer demonstrates superior analytical precision with 96% EFLM compliance in oncology
- A highly sensitive and precise RUO immunoassay for measuring p-Tau217 in blood samples
- DxI 9000 Analyzer achieves 6σ performance for high sensitivity Troponin I measurement
- DxI 9000 Analyzer assay performance meets new CLIA 2024 goals with highest proportion of Six Sigma performance
- Evaluation of the Access HIV Ag/Ab combo assay with highly sensitive HIV-1 p24 detection shows 100% sensitivity
- 92% of patients could have received ABX within 3 hours of ED presentation
- PrecisionVision Technology shows a 2.2% CV mean variance across the range
- SimpleSolve Advanced Instrument-Guided Troubleshooting on the DxI 9000 Analyzer
-
Study showed up to 20-fold improvement of the Access AMH assay on the DxI 9000 Immunoassay Analyzer
-
DxI 9000 Analyzer’s high sensitivity = reduction of required sample and reagent volumes for some immunoassays
-
New, Fully Automated, High-throughput, RUO Immunoassay for measuring Plasma GFAP on Access 2 & DxI 9000 Analyzers
-
DxA 5000 Reduces TAT in Multiple Sample Types Receiving by a Typical Blood Sciences Lab
- Avoiding Unnecessary Administration of Antibiotics
- Hospital Reduces Average TAT by 83% with HbA1c Advanced
Learn about important disease states and diagnostic innovations.
Immunoassay
A study comparing results of 3 assays showed improved sensitivity & precision on the DxI 9000 analyzer
Immunoassay
Study of Anti-HCV Assay on DxI 9000 Access Immunoassay Analyzer shows 100% specificity
Automation
DxA 5000 Reduces TAT in Multiple Sample Types Receiving by a Typical Blood Sciences Lab
Past Studies
- A tool for sepsis ID in ED cancer patients
- Using DxH 900 data to help aid in AML ID
- High MDW results in patients with occult symptoms ⬇ time to antibiotics by ~1 h
- >95% Achieved criteria for analytical agreement based on “Allowable Total Difference Zone” following Assay Migration Guidance
- Study shows including Scopio’s FF-PBS application saves 12.76 work hours/month
- Study Shows Differences in the 3 FLC Assays Can = Clinically Different Results
- Study of 1,049 patients excludes AMI 3 hours after ED presentation with hsTnI
- Study establishes age-and sex-specific pediatric reference intervals for 47 hematologic parameters
- Study validates semi-quantitative diagnostic method with 90% sensitivity
- Multi-center study finds 87.59% auto verification pass accurate rate
- Study shows abnormal MDW increased probability of sepsis
- Study shows 100% sensitivity for two accelerated diagnostic pathways
- Preventing and responding COVID-19 on college campuses
- Implementation pooled surveillance testing program asymptomatic sars-cov-2
- Results of universal testing of 1970 nursing home residents
- Study of 3.2-million people shows seropositivity = decreased risk of infection
- Hospital in South Korea improves workflow efficiency with DxC 700 AU
- Identifying a Decreased Probability of Sepsis Diagnosis
- Abnormal MDW 27.3 Changed Patient’s Trajectory
- MDW Biomarker Identified Risk of Severe Infection
- U.K. hospital reduces patient wait times following introduction of Access hsTnI
Disclaimer: Articles are presented for educational purposes only and are not intended to promote any Beckman Coulter product or service. Unless otherwise indicated, Beckman Coulter did not provide funding for these studies.
